With every passing prototype and development kit for the Oculus Rift head-mounted display (HMD) creator Oculus VR has tackled more and more of virtual reality’s (VR) biggest issues. Problems such as motion sickness may not have been completely solved but the company has drastically reduced the effects using low latency displays and innovative software solutions. Despite the fact that Oculus VR will one day be competing against a range of VR HMDs, it’s hoping that other companies are taking the same approach.
Oculus VR CEO Brendan Iribe said as much during a recent talk at the Web Summit in Dublin, as reported by The Guardian. “We’re really looking forward to this as an industry that takes off… A number of companies will come in, even companies we haven’t heard of yet two or three or five years down the road,” he said.
“At the same time we’re a little worried about some of the bigger companies putting out product that isn’t quite ready. That elephant in the room is disorientation and motion sickness.”
Of course, one such company is Sony Computer Entertainment (SCE) which is currently working on its Project Morpheus HMD for PlayStation 4. When it was first revealed the kit was close to the Oculus Rift’s newly-revealed second development kit (DK2). That said, the company is yet to reveal any further updates to its prototype while Oculus VR has surpassed DK2 with its Crescent Bay kit, revealed at the Oculus Connect developer conference in September 2014.
Iribe mentioned that Oculus VR has even invited SCE to sample the latest prototype of the Oculus Rift, taking the opportunity to ask the company: “Please make sure your product is as good or close!”
Iribe’s comments reflect SCE Head of Worldwide Studios’ Shuhei Yoshida’s own remarks earlier in the year that the two companies sample each other’s work. It’s not yet clear just when SCE might reintroduce an updated version of Project Morpheus or provide details on a release date. VRFocus will continue to follow both HMDs, reporting back with any further updates on them both.